EBSCO Logo
Connecting you to content on EBSCOhost
Title

Bornyl Derivatives of p -(Benzyloxy)Phenylpropionic Acid: In Vivo Evaluation of Antidiabetic Activity.

Authors

Kuranov, Sergey; Luzina, Olga; Khvostov, Mikhail; Baev, Dmitriy; Kuznetsova, Darya; Zhukova, Nataliya; Vassiliev, Pavel; Kochetkov, Andrey; Tolstikova, Tatyana; Salakhutdinov, Nariman

Abstract

A series of bornyl derivatives of p-(benzyloxy)phenylpropionic acid were prepared, and their hypoglycemic activities were examined by an oral glucose tolerance test in mice. The results of this test revealed two compounds, 1 and 3, that can reduce the blood level of glucose similarly to reference compound vildagliptin. Both compounds were tested in an experiment on mice with metabolic disorders: the C57BL/6Ay strain. Along with hypoglycemic properties, the two compounds showed different abilities to correct lipid metabolism disorders. In silico prediction revealed that the studied substances are most likely bifunctional multitarget hypoglycemic compounds whose mechanism of action is based on a pronounced reduction in insulin resistance and a strong incretin-mimetic effect. The difference in the size of effects of these compounds on biochemical parameters of blood in the experiment on C57BL/6Ay mice was in good agreement with the computational prediction of the priority ranking of biological targets for these compounds. These results indicate that bornyl derivatives of p-(benzyloxy)phenylpropionic acid have a good potential as new agents for diabetes mellitus treatment due to their hypoglycemic and lipid-normalizing properties.

Subjects

LIPID metabolism disorders; GLUCOSE tolerance tests; BLOOD sugar; METABOLIC disorders; TYPE 2 diabetes

Publication

Pharmaceuticals (14248247), 2020, Vol 13, Issue 11, p404

ISSN

1424-8247

Publication type

Academic Journal

DOI

10.3390/ph13110404

EBSCO Connect | Privacy policy | Terms of use | Copyright | Manage my cookies
Journals | Subjects | Sitemap
© 2025 EBSCO Industries, Inc. All rights reserved